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Immune responseSwine influenza A virus (SwIV) infection has considerable economic and animal welfare consequences
and, because of the zoonotic potential, can also have public health implications. The 2009 pandemic
H1N1 ‘swine-origin’ infection is now endemic in both pigs and humans. In Europe, avian-like H1avN1,
human-like H1huN2, human-like swine H3N2 and, since 2009, pandemic H1N1 (pH1N1) lineage viruses
and reassortants, constitute the dominant subtypes. In this study, we used a swine pH1N1 challenge virus
to investigate the efficacy of whole inactivated virus vaccines homologous or heterologous to the chal-
lenge virus as well as a commercial vaccine. We found that vaccine-mediated protection was most effec-
tive when vaccine antigen and challenge virus were homologous and correlated with the specific
production of neutralising antibodies and a cellular response to the challenge virus. We conclude that
a conventional whole inactivated SwIV vaccine must be antigenically matched to the challenge strain
to be an effective control measure.
Crown Copyright  2019 Published by Elsevier Ltd. This is an open access article under the Open
Government License (OGL). (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/
3/).1. Introduction viruses and the frequent re-introductions of strains from theSwine Influenza A virus (SwIV) infection is of economic impor-
tance to the pig industry and may also affect public health, because
of the zoonotic potential. In particular, infection of humans with
the 2009 pandemic H1N1 (pH1N1) ‘swine-origin’ virus has been
a serious ‘One Health’ concern in recent years. This virus is now
endemic in pigs and humans [1].
Pigs can be infected by both avian- and mammalian-origin
influenza A viruses and are a key intermediate host species in
the adaptation of avian influenza viruses to mammals, including
humans. In addition, SwIV strains display greater genetic diversity
in comparison to influenza A viruses circulating in the human pop-
ulation at any one time. This increased genetic diversity is likely
linked to the permissiveness of swine to a wider spectrum ofhuman population [1,2]. Vaccination of swine could be a key ele-
ment for mitigating influenza A disease risks to both human and
animal health [1–4].
SwIV vaccine composition and application for controlling dis-
ease varies [2,4]. Lack of vaccine use by swine producers is attrib-
uted to the short lifespan of meat production pigs, the requirement
to vaccinate in the absence of maternally-derived antibodies and
the need for conventional whole inactivated virus (WIV) vaccines
to be antigenically matched to circulating virus lineages in order
to be effective [2,4]. Because of the genetic diversity of circulating
SwIVs, vaccines containing a defined number of antigens can only
provide limited cross-protective immunity [1,2]. In addition WIV
vaccine efficacy is constrained as it depends largely on the gener-
ation of neutralising IgG antibodies to the highly variable regions
of the major viral envelope hemagglutinin (HA) antigen [4]. Such
vaccines reduce clinical disease following infection by antigeni-
cally matched strains, but complete sterile immunity is rarely
observed [2,4].
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trivalent vaccine, licensed in 2010, which incorporates H1avN1
and H3N2 antigens isolated in 2003 as well as a reassortant antigen
(H1huN2) with human-origin H1 and N2 gene segments. This vac-
cine, Gripovac3 is now licenced as Respiporc Flu3 (web references
1, 2). A veterinary monovalent vaccine against the swine pH1N1
influenza A virus was licenced in the UK in 2017 (Respiporc FLUpan
H1N1, web reference 3). Manufacturers are required to follow the
full licensing procedure in order to change vaccine strains, which
creates a regulatory hurdle for updating of SwIV vaccine composi-
tion. Therefore, commercially available vaccines do not always
antigenically match contemporary circulating strains [4]. Current
research efforts are directed at developing broadly cross-
protective vaccines capable of stimulating both humoral and cellu-
lar arms of the immune system.
To understand the strengths and limitations of current SwIV
vaccines as a disease control tool, this study assessed the protec-
tive efficacy and reduction in virus shedding provided by three dif-
ferent vaccines upon challenge of pigs with a swine pandemic 2009
influenza A virus isolate and the humoral and cellular immune
responses. The three vaccines were a commercially available triva-
lent vaccine (Gripovac3) and two monovalent WIV vaccines anti-
genically homologous or heterologous to the challenge strain.
2. Materials and methods
Influenza A virus strains used to generate the whole inactivated
virus (WIV) vaccines were a pandemic 2009 H1N1 isolate,
A/swine/England/1353/2009 (pH1N1) [3], and a Eurasian
avian-like H1N1 isolate, A/swine/England/453/2006 (H1avN1) [5].
Vaccine antigen was prepared from virus grown in SPF embry-
onated chicken eggs and inactivated with beta-propiolactone
(BPL) [6].The antigenic content was quantified and expressed in
HA units per ml (HAU/ml). WIV vaccines were formulated in an
oil-in-water adjuvant, TS6 (web reference 4, CEVA), and were
formulated in 1 ml with a 1:2 antigen to TS6 ratio. Gripovac3, is
a WIV vaccine incorporating three European-origin SwIV subtypes,
H1avN1 and H1huN2 and H3N2, isolated between 2000 and 2003,
formulated in carbomer anionic polymer adjuvant (Table 1). An
H1huN2 subtype antigen A/Sw/Eng/438207/94, was used to
monitor the immune response to Gripovac3.
All in vivo studies were conducted at APHA following ethical
approval according to the U.K. Animals (Scientific Procedures)
Act, 1986 and the ARRIVE guidelines. Sixteen Landrace cross
female pigs of high health status were verified to be negative for
influenza A virus infection by matrix gene real-time RT-PCR [7]
and for antibodies by an HA inhibition (HI) test [8]. Pigs were ran-
domised into four groups (n = 4) and vaccinated at 6.5 weeks
(0 days post vaccination (dpv)) and 21dpv. The vaccines (Table 1)Table 1
Summary of pig groups and vaccines administered.
Group Vaccine virus subtype Strain(s)
1 Homologous
pH1N1 A/swine/England/1353/2009
2 Heterologous
H1avN1 A/swine/England/453/2006
3 Gripovac3
H1avN1 A/swine/Haselünne/IDT2617/20
H1huN2 A/swine/Bakum/1832/2000
H3N2 A/swine/Bakum/IDT1769/2003
4 Adjuvant control
a HAU, log2 hemagglutination units.
b GMNU, log2 geometric mean of neutralising units induced in Guinea pigs after immwere administered into the trapezius muscle, 25–30 mm posterior
to the ear using a 1 in., 19G needle. Antigen content was increased
for the boost when no adverse reaction to the primary vaccination
occurred.
Pigs were challenged intranasally, as in previous studies [9–11].
On 69dpv, a dose of 1x107 TCID50 pH1N1 virus was administered to
each pig using a MAD300 (Teleflex) which delivers an atomised
spray of droplets 30–100 lm in diameter [12]. This non-invasive
method of challenging alert pigs was used, as previously
[5,11–13], to mimic the natural route infection. Animals were
monitored daily following challenge on 0 days post-infection
(dpi) according to a clinical scoring system [13]. Animals were
euthanized at 10dpi or 79dpv with an overdose of intravenous
pentobarbital sodium.
Serum samples were obtained pre-vaccination, weekly between
boost and challenge and at 1, 3, 7 and 9 dpi and stored at 80 C.
Heparin anticoagulated blood samples were taken for peripheral
blood mononuclear cells (PBMC) isolation at 0, 14, 28, and 63dpv
and 3 and 9dpi. Four nasal swabs (two per nostril) were taken at
14, 28 and 56dpv, before challenge and daily after challenge until
euthanasia. Dry swabs were stored at 80 C. Daily nasal swabs
were processed together by immersion in 2 ml of Leibovitz L-15
medium, containing 1% FBS, 100U/ml penicillin and 100 lg/ml
streptomycin (Gibco). Swab suspensions were aliquoted and stored
at 80 C for analysis.
RNA extracted from nasal swab suspensions using the RNeasy
mini kit (Qiagen) was quantified by RRT-qPCR [7] for the influenza
A virus M gene using an MxPro 3000P instrument and MxPro anal-
ysis software (Agilent). RNA quantity was expressed as relative
equivalent units (REU) of RNA using a standard 10-fold dilution
series of RNA purified from the virus stock used for challenge, with
known titre. Samples with ‘no Cycle threshold (Ct)’ or negative REU
value were assigned a value of 0 once log10 transformed. Although
REU values measure the amount of viral RNA present and not infec-
tivity, it may be inferred from the linear relationship with the dilu-
tion series that they are proportional to the amount of virus
present. Area under the curve (AUC) was calculated using Graph-
Pad Prism software to evaluate the total shedding of viral RNA.
Vaccine groups comparisons for height of shedding peak, AUC
and cellular response, used a pairwise permutational t-test from
the package ‘RVAideMemoire 0.9-550 in R3.1.1. We used 1000 per-
mutations and the p-value was adjusted for multiple testing [14].
Antibody titres were measured using HI and virus neutralisa-
tion (VN) [11]. HI antigens were the homologous and heterologous
vaccines as well as an H1huN2 SwIV strain, A/Sw/Eng/438207/94.
VN was measured against the pH1N1 challenge virus. Results are
expressed as the Geometric Mean Ratio (GMR) for each group,
calculated relative to the baseline titre. PBMC were isolated from
heparinized venous blood and cryopreserved. Samples wereVaccination Boost Adjuvant
1024 HAUa 3072 HAU TS6
1024 HAU 3072 HAU TS6
03 10.22 GMNUb 10.22 GMNUb Carbomer
12.34 GMNU 12.34 GMNU 971 P NF
10.53 GMNU 10.53 GMNU
TS6 in PBS
unisation twice with 0.5 ml of this vaccine.
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analysed using a Porcine IFN-c ELISpot assay [15].
3. Results
We evaluated the protective efficacy of three vaccine candi-
dates: homologous inactivated, heterologous inactivated (both in
TS6 adjuvant) and the commercial trivalent Gripovac3 vaccine
delivered as intra-muscular vaccinations 21 days apart. Control
animals received TS6 adjuvant only (Table 1). Animals were chal-
lenged 69 days after the first vaccination. Vaccination and chal-
lenge produced no adverse reactions in any group and clinical
scores transiently reached no more than 3 out of a possible maxi-
mum of 20 for 2 animals (data not shown).
To assess viral RNA shedding, viral RNA present in daily nasal
swab samples was quantified (Fig. 1a–d). Viral RNA, expressed as
REU, correlates with the amount of infectious virus, if the infec-
tious titre is above approximately 100pfu/ml (Fig. S1). Despite vari-
ation between individual animals, viral RNA shedding, measured
by the AUC (Fig. 1e and f), was significantly reduced only in theFig. 1. Viral shedding. Viral shedding levels in nasal swabs were assessed daily by RRT-q
Individual pig and group mean REU graphs for groups receiving (a) homologous WIV vac
are shown. Mean virus shedding (e) and area under the curve (AUC) analysis (f) revealed
vaccinated with the homologous WIV vaccine. Vertical bars represent ±SEM.pigs vaccinated with the homologous WIV vaccine. When com-
pared to pigs which received the homologous WIV vaccine, shed-
ding was significantly elevated by 88.6% (P = 0.045) in the
heterologous WIV vaccine group, 91.0% (P = 0.048) in the Gripo-
vac3 vaccine group or 92.5% (P = 0.045) in the adjuvant control
group. The peak of viral shedding was delayed and significantly
lower in the homologous WIV group when compared to the
heterologous WIV vaccine (P = 0.042), Gripovac3 vaccine
(P = 0.039) or adjuvant (P = 0.039) groups.
The serum antibody HI titres were obtained for all samples
using the same antigen in each WIV vaccine and a SwIV H1huN2
representing one antigen in Gripovac3 (Fig. 2a–c). A specific
humoral response to each vaccine antigen was detected in the
group vaccinated with the cognate antigen peaking 7d post-
boost. The response was strongest against the TS6-adjuvanted for-
mulations (Fig. 2a and b) and lower in the Gripovac3 group
Fig. 2c. Following challenge with the pH1N1 virus, responses to
the cognate vaccine antigen were rapidly boosted by 9dpi in all
vaccine groups compared to the adjuvant only group, confirming
that there was efficient priming by all vaccines.PCR and amounts are expressed as log10 Relative equivalent units (REU) of viral RNA.
cine, (b) heterologous WIV vaccine, (c) Gripovac3 or (d) TS6 adjuvant control alone
that virus shedding was significantly reduced (**P < 0.05) in the group that had been
Fig. 2. Serological analysis. Longitudinal serum samples were assessed by
hemagglutination inhibition (HI) against (a) the homologous antigen, pH1N1
(A/swine/England/1353/2009), (b) the heterologous antigen, H1avN1 (A/swine/
England/453/2006) and (c) a representative H1huN2 antigen, A/swine/England/
438207/1994. The Geometric Mean Ratio (GMR) for samples relative to the 0dpv
sample for each corresponding animal is shown. Virus neutralisation (VN) titres
(d) were evaluated for serum samples using the homologous pH1N1 challenge
strain A/swine/England/1353/2009.
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differed between the vaccinated groups (Fig. 2d). The homologous
WIV vaccine elicited high titres of neutralising antibodies to the
challenge strain, but with different kinetics to the HI antibody titre.
In the other vaccine groups, although pH1N1 virus infection eli-cited a humoral response, the response was directed against the
vaccine antigen with a lower specific neutralising ability against
the challenge strain.
Analysis of the cellular response (Fig. 3a) showed, as expected,
that the homologous WIV vaccine group produced the highest
virus-specific responses whereas lower responses were seen in
the remaining groups. After challenge, the highest response was
observed in the homologous WIV vaccine group when stimulated
by vaccination and homologous virus challenge within 3 days
(Fig. 3b) and was significant (p = 0.049) relative to all other groups
using a pairwise permutation test. The heterologous WIV vaccine
group also displayed a significantly different response (p = 0.049)
relative to the adjuvant control group. There was no significant dif-
ference in the response measured between groups at 9dpi (Fig. 3c).
This result likely reflected the primary cellular response to infec-
tion rather than a vaccine-stimulated response.4. Discussion
This study confirms that a conventional WIV vaccine needs to
be antigenically matched to the challenge virus lineage in order
to be efficacious, as reported previously [11,16]. A 10 week interval
separated the first vaccination and virus challenge to be represen-
tative of the lifespan of a food-production pig. Intranasal challenge
with a pH1N1 strain produced minimal clinical signs, as observed
previously in mature animals [11,12]. Viral shedding was observed
in all groups but in the homologous vaccine group, was signifi-
cantly reduced as indicated by the AUC analysis of the viral RNA
shedding profiles, in keeping with other pH1N1 vaccination-
challenge studies [11,16]. In a field situation, it is unknown
whether this level of shedding would support onward transmission
of the virus, although successful control of a pH1N1 outbreak with
a homologous vaccine has been reported [17]. The Gripovac3 and
heterologous vaccines, which contained an H1avN1 antigen, did not
significantly reduce shedding following infection with the diver-
gent lineage pH1N1 SwIV, as reported previously for Gripovac3
[11].
Humoral and cellular immune responses to influenza virus
infection were elicited following challenge, indicating that the
WIV vaccines efficiently primed the immune system. We found
that vaccinated pigs developed hemagglutinating antibodies to
the corresponding vaccine antigen in all cases. Following pH1N1
challenge, HI titre was elevated against the original priming (vac-
cine) antigen, rather than the challenge strain. This result could
be indicative of back-boosting (reviewed in [2]) and corresponds
to previous observations with vaccination-challenge studies [10].
The neutralising antibody response distinguished the homologous
vaccine group from the other groups, although greater levels of
cross-reactive neutralising antibodies have been detected in other
studies [9–11]. In our study, the neutralising antibody response
correlated with the decrease in nasal shedding of viral RNA and
is potentially a better predictor of vaccine efficacy.
The cellular immune response to vaccination and challenge is
not frequently assessed [4]. In this study the homologous
vaccinated-challenge group developed a robust cellular response
to the cognate antigen, as expected, and the post-challenge kinetics
mirrored that of the humoral response. This indicates that the
cellular immune response may also have played a role in
vaccine-mediated protection, but the experiments performed here
cannot determine the relative contribution of either humoral or
cellular immunity to protection.
During this study, clinical signs corresponding to vaccine-
associated enhanced respiratory disease (VAERD) [18] were not
observed. VAERD has been reported in pigs when WIV vaccines
in an oil-in-water adjuvant has been used followed by challenge
Fig. 3. Cellular response. IFN-c ELISpot analysis of the PBMC response is expressed
as SFC/106 cells to the pH1N1 A/swine/England/1353/2009 antigen (a) for the
duration of the study or specifically for (b) 72dpv (3dpi) and (c) 78dpv (9dpi).
Horizontal lines indicate significant differences (**p = 0.049) between groups and
vertical bars represent ±SEM.
2292 H.E. Everett et al. / Vaccine 37 (2019) 2288–2293with a virus incorporating an antigenically related HA envelope
protein. Recently, VAERD has been linked to factors including the
production of non-neutralising HA-specific antibodies without
inhibitory anti-NA antibodies [2] and the formulation of oil-in-
water adjuvants [19]. It is unknown which aspects of the current
study design may have avoided disease exacerbation.
Pigs are a key species and an important veterinary host for the
study and control of mammalian influenza viruses. Inter-species
transmission and reassortment events frequently occur between
pigs and humans, increasing the risk of emergence of novel viruses.
For SwIV vaccination to serve as an effective control measure inreducing disease burden and pandemic influenza risk, a structured
approach is needed for regular updating of vaccine composition
[1].5. Conclusions
Currently available WIV vaccines need to be antigenically
matched to circulating influenza virus lineages in order to be effi-
cacious. Improvement in vaccination strategies that reduce swine
influenza A virus shedding and therefore the likelihood of onward
transmission of infection, would be beneficial to swine health and
the agricultural sector. Our results reinforce the need for the devel-
opment of broadly cross-reactive influenza virus vaccines.
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ture of infectious virus can be inconsistent. This observation could
indicate the presence of defective, non-infectious virus particles
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bodies, which can prevent the detection of infectious virus. Supple-
mentary data to this article can be found online at https://doi.org/
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